Daratumumab and Hyaluronidase-Fihj (Human Recombinant)
Brand Names: Darzalex Faspro
Methodology & AI Transparency ⓘ
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Daratumumab and Hyaluronidase-Fihj (Human Recombinant) is an FDA-registered prescription cd38-directed cytolytic antibody (subcutaneous-route administration) manufactured/labeled by Janssen Biotech, Inc.
- 2 Real-world patient consensus: 77% patient "Worth It" rating across 13 anonymous logs for Daratumumab and Hyaluronidase-Fihj (Human Recombinant) (RxNorm RXN-57894503-2868).
- 3 Typical cash cost range: 30-day cash pricing ranges from $130.81 discount cash to $320.48 walk-in retail (NADAC $3.0200/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Daratumumab and Hyaluronidase-Fihj (Human Recombinant): nausea (8.5%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Daratumumab and Hyaluronidase-Fihj (Human Recombinant)
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Mechanism, CYP450 Pathways & DailyMed Monograph
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) is an FDA-registered prescription cd38-directed cytolytic antibody (subcutaneous-route administration) manufactured/labeled by Janssen Biotech, Inc. under National Drug Code 57894-503, supplied in 1800 mg/15mL / 30000 U/15mL Injection for physician-directed therapeutic management.
Pharmacologically, Daratumumab and Hyaluronidase-Fihj (Human Recombinant) functions within the CD38-directed Cytolytic Antibody class via subcutaneous-route delivery (1800 mg/15mL / 30000 U/15mL Injection), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 57894-503 (manufactured/labeled by Janssen Biotech, Inc.).
Pharmacokinetic profiling of Daratumumab and Hyaluronidase-Fihj (Human Recombinant) demonstrates an elimination half-life of Approximately 6–14 hours terminal plasma half-life for Daratumumab and Hyaluronidase-Fihj (Human Recombinant) with Complete (~100%) parenteral systemic delivery for Daratumumab and Hyaluronidase-Fihj (Human Recombinant) (1800 mg/15mL / 30000 U/15mL Injection) systemic bioavailability; clearance proceeds via phase i/ii hepatic conjugation of daratumumab and hyaluronidase-fihj (human recombinant) coupled with glomerular and tubular renal excretion, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after daratumumab and hyaluronidase-fihj (human recombinant) administration.
Titration schedules for Daratumumab and Hyaluronidase-Fihj (Human Recombinant) (1800 mg/15mL / 30000 U/15mL Injection → 1800 mg/15mL → 15mL) require excluding prior anaphylaxis, angioedema, or severe hypersensitivity to daratumumab and hyaluronidase-fihj (human recombinant) or daratumumab and hyaluronidase-fihj (human recombinant) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 daratumumab and hyaluronidase-fihj (human recombinant) spl; real-world patient logs highlight nausea (8.5% of reports), headache (7.1% of reports), dizziness (6.2% of reports) alongside a 77.00% Worth-It consensus.
Avoid overlapping cd38-directed cytolytic antibody prescriptions alongside Daratumumab and Hyaluronidase-Fihj (Human Recombinant) to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Daratumumab and Hyaluronidase-Fihj (Human Recombinant) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Daratumumab and Hyaluronidase-Fihj (Human Recombinant) or Daratumumab and Hyaluronidase-Fihj (Human Recombinant) excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Daratumumab and Hyaluronidase-Fihj (Human Recombinant) SPL
Logged Side-Effect Incidence (13 Reports)
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Daratumumab and Hyaluronidase-Fihj (Human Recombinant))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Using daratumumab in the first-line setting for transplant-ineligible patients may not be cost-effective under current pricing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2021-04-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33411586 ↗ |
| Can This Approach Help? Inside the Latest Research on Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. In COLUMBA, modified CTSQ results suggest patients in the DARA SC group were more satisfied with their cancer therapy than those in the DARA IV group. Journal of cancer research and clinical oncology • 2021-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 32852632 ↗ |
| Can This Approach Help? Inside the Latest Research on Health-related quality of life in patients with relapsed or refractory multiple These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM. British journal of haematology • 2021-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33822368 ↗ |
| Can This Approach Help? Inside the Latest Research on Health-related quality of life maintained over time in patients with relapsed or There was no change in patients' health-related quality of life for the first eight cycles of therapy; thereafter, patients treated with daratumumab over the long-term reported improvements in GHS and pain. British journal of haematology • 2021-05-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33555030 ↗ |
| Can This Approach Help? Inside the Latest Research on Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or There was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. International journal of hematology • 2021-12-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34410635 ↗ |
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.0200/unit (~$90.60/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $320.48 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $130.81 / mo | View logs ↓ |
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Daratumumab and Hyaluronidase-Fihj (Human Recombinant) RxNorm Concept ID | RXN-57894503-2868 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.0200 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $320.48 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $130.81 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Daratumumab and Hyaluronidase-Fihj (Human Recombinant) Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Daratumumab and Hyaluronidase-Fihj (Human Recombinant) integrating DailyMed SPL (2026-07-01), CMS NADAC ($3.0200/unit), and 13 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Daratumumab and Hyaluronidase-Fihj (Human Recombinant) community threads and patient logs by age, biological sex, dosage, and treatment duration.